Onkologie. 2009:3(4):227-229

Metronomic therapy as new challange in medical oncology

Danica Bronišová³, MUDr. Peter Múdry³, prof. MUDr. Jaroslav Štěrba Ph.D³, Viera Bajčiová³, Dalibor Valík¹, Lenka Dubská², MUDr. Pavel Mazánek³, Petr Lokaj³, Karel Zitterbart³

¹ Masarykův onkologický ústav, Brno

² Oddělení laboratorní medicíny Masarykův onkologický ústav Brno

³ Klinika dětské onkologie LF MU a FN, Brno

The outcome of patients with progressive cancer, relaps or high risk tumor remains very poor. For these patients metronomic chemotherapy

begins to be suitable alternative to conventional chemotherapy. Metronomic therapy refers to long term, chronic administration

of low doses of conventional cytotoxic agents. Unlike „dose dense“ chemotherapy, it is minimally toxic and can be taken on out-patient

basis. Mechanism responsible for the antitumor effect of metronomic therapy is under investigation, it is thought to be combination of

antiangiogenic effect, stimulation of the immune response and direct cytotoxic action on tumour cells. This review describes the results

of preclinical and clinical studies with the intention of usage in pediatric oncology.

Keywords: metronomic therapy, angiogenesis, relaps, child.

Published: November 1, 2009  Show citation